Tag Archives: reimbursement

Drug Reimbursement: Make Room at the Table for Patients and Researchers

At last week’s Partnering for Cures conference held in New York City, several expert panels discussed new angles of approaching solutions to disease, encouraging investment and mitigating inefficiencies in the delivery of medicines within the current healthcare system. A highlight was a session on  “Reimbursement: Can Value Drive Innovation?,” which looked at  defining value in […]
Posted in Events, FDA, healthcare, Market Access, pricing | Also tagged , , , , , , , , , , , , , , , | Leave a comment

Specialty Drugs: A Tempting Target, But What to Do?

A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, life-altering diseases.  The financial and reputational stakes for players in this hotly contested commercial space are high, compounded by a startling lack of awareness of the incentives that drive specific […]
Posted in Biotech, Market Access, Meetings, pricing, Strategy | Also tagged , , , , , , , | Leave a comment

Specialty Drugs and Reimbursement

To maximize return on investment, pharma must think strategically about reimbursement channels and how new specialty products will perform in one versus another. By 2018, the amount health insurers spend per person on specialty, or biologic drugs, will equal or surpass the amount spent on traditional products, according to a new report. With the emergence […]
Posted in Biotech, Strategy | Also tagged , , | Leave a comment

Ethics in Drug Innovation: The First Hurdle is Trust

By Ansis Helmanis Ethics is a matter of trust, which in the regulatory space requires transparency and openness among all stakeholders, including patients and industry.  This was the consensus of FDA Commissioner Margaret Hamburg and European Medicines Agency (EMA) Executive Director Guido Rasi, both of whom shared the podium with Nobel Laureate Professor Elie Wiesel […]
Posted in Europe, Events, FDA, Global, Guest Blog, healthcare, leadership, Market Access, Patient Communication, pricing, Regulatory | Also tagged , , , , , , , | Leave a comment

EU Pins Hopes on HTA Network for Consensus on Value

The European Union’s proposed health technology assessment network to encourage “cooperation and exchange of scientific information among member states” is a significant step, says Reflector. But, as far as standardizing an approach to value is concerned, will it be a damp squib?
Posted in Europe, Global, Guest Blog, pricing | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta